title: Vemurafenib-induced neutrophilic panniculitis.
abstract: Vemurafenib is a targeted therapy, used in patients with metastatic cutaneous melanoma who carry the BRAF V600E mutation, with a relative reduction of 63% in the risk of death. Several adverse events have been described previously, such as photosensitivity or squamous-cell carcinomas. Two cases of panniculitis have been reported recently with two different selective BRAF inhibitors. We report two cases of neutrophilic panniculitis in patients treated by vemurafenib for a metastatic melanoma. Clinical and biological examinations showed no indications for an immune nor an infectious cause of neutrophilic panniculitis. Thus, we believe that vemurafenib caused this panniculitis. Treatment with vemurafenib was maintained in both patients because of the clinical and radiological tumoral responses. One patient showed spontaneous recovery, whereas the other patient presented several recurrences of panniculitis. We believe that physicians should be aware of this cutaneous side effect of vemurafenib, but it should not lead to discontinuation of this treatment.
authors: Department of Dermatology, St-Louis Hospital, Paris, France. jb.monfort@wanadoo.fr
authors: Jean-Benoît
authors: JB
authors: Monfort
authors: Cécile
authors: C
authors: Pagès
authors: Pierre
authors: P
authors: Schneider
authors: Bart
authors: B
authors: Neyns
authors: Christelle
authors: C
authors: Comte
authors: Martine
authors: M
authors: Bagot
authors: Marie-Dominique
authors: MD
authors: Vignon-Pennamen
authors: Manuelle
authors: M
authors: Viguier
authors: Céleste
authors: C
authors: Lebbé
mesh_terms: D000328:Adult; D000368:Aged; D005260:Female; D006801:Humans; D007211:Indoles / Q000008:administration & dosage / Q000009:adverse effects*; D008545:Melanoma / Q000188:drug therapy; D009504:Neutrophils / Q000473:pathology; D015434:Panniculitis / Q000097:blood / Q000139:chemically induced* / Q000188:drug therapy; D012878:Skin Neoplasms / Q000188:drug therapy; D013449:Sulfonamides / Q000008:administration & dosage / Q000009:adverse effects*; D000077484:Vemurafenib
chemical_list: D007211:Indoles; D013449:Sulfonamides; D000077484:Vemurafenib